SUN Zhonghui, WANG You, DUAN Haijie, TAN Yuegui, LIANG Le, YAO Hongping. A case study of spironolactone induced gynecomastia in one male patient with cirrhosis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 165-166,170. doi: 10.3969/j.issn.1006-0111.2017.02.017
| Citation:
|
SUN Zhonghui, WANG You, DUAN Haijie, TAN Yuegui, LIANG Le, YAO Hongping. A case study of spironolactone induced gynecomastia in one male patient with cirrhosis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 165-166,170. doi: 10.3969/j.issn.1006-0111.2017.02.017
|
A case study of spironolactone induced gynecomastia in one male patient with cirrhosis
- 1.
Department of Pharmacy, First Hospital Affiliated to Xi'an Jiaotong University, Xi'an 710061, China;Department of Pharmacy, No.5 Hospital of Xi'an City, Xi'an 710082, China
- 2.
Department of Pharmacy, No.5 Hospital of Xi'an City, Xi'an 710082, China
- 3.
Department of Pharmacy, No.1 Hospital of Xi'an City, Xi'an 710002, China
- 4.
Department of Pharmacy, First Hospital Affiliated to Xi'an Jiaotong University, Xi'an 710061, China
- Received Date: 2016-09-06
- Rev Recd Date:
2017-01-05
-
Abstract
Objective To study one male patient with cirrhosis for spironolactone induced gynecomastia and promote clinical pharmacists providing better pharmaceutical cares. Methods Based on the patient's diseases and medication history, clinical pharmacists searched related literature and analyzed the cause of gynecomastia for the patient. Results The patient's breast pain was relieved and finally disappeared after termination of spironolactone. Therefore, spironolactone was suspected to be the drug to cause gynecomastia. Conclusion Clinical pharmacists can improve pharmaceutical cares by carefully monitoring the adverse reactions and selecting appropriate medications.
-
References
|
[1]
|
Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction:a systematic review of randomized clinical trials[J]. Eur Heart J, 20089,30(4):469-477. |
|
[2]
|
Sinclair M, Grossmann M, Gow PJ, et al. Testosterone in men with advanced liver disease:Abnormalities and implications[J]. J Gastroenterol Hepatol, 2015,30(2),:244-251. |
|
[3]
|
Le HH, El-Khatib C, Mombled M, et al. Impact of aldosterone antagonists on sudden cardiac death prevention in heart failure and post-myocardial infarction patients:A systematic review and Meta-analysis of randomized controlled trials[J].PloS one, 2016,11(2):e0145958. |
|
[4]
|
白厚喜,林鹂鸣,徐恩斌,等.男性肝硬化患者乳房发育45例分析[J]. 国际消化病杂志, 2011,31(3):185-186. |
|
[5]
|
Seferovic PM, Pelliccia F, ZivkovicI, et al. Mineralocorticoid receptor antagonists, a class beyond spironolactone-Focus on the special pharmacologic properties of eplerenone[J]. Int J Cardiol,2015,200(11):3-7. |
|
[6]
|
方红贤. 螺内酯治疗皮肤病578例分析[J]. 同济大学学报(医学版), 2001,22(6):49,60. |
|
[7]
|
Batterink J, Stabler SN, Tejani AM, et al. Spironolactone for hypertension[J]. Cochrance Databse Syst Rev, 2010,8:CD008169. |
|
[8]
|
Becker,ML, Visser LE, Van G elder T, et al. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or=55 years[J]. Drugs Aging, 2008,25(2):145-152. |
|
[9]
|
张丹, 段思栋, 小剂量螺内酯治疗冠心病慢性心力衰竭的疗效及安全性分析[J]. 中国初级卫生保健, 2014,28(6):112-114. |
|
[10]
|
陈富超,方宝霞,李开俊,等.药源性溢乳和男性乳房发育症系列病例文献分析[J].药物流行病学杂志,2006,15(6):348-349. |
|
[11]
|
Pelliccia F, Patti G Rosano G, et al. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension:Systematic review and meta-analysis[J]. Int J Cardiol, 2014,177(1):219-228. |
|
[12]
|
陆人杰, 朱珊梅, 唐风雷. 1例螺内酯致男性乳房发育症的病例分析[J].医学信息, 2013,28:678. |
-
-
Proportional views
-
DownLoad: